Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Anika Therapeutics Inc.

35 indications, side-by-side phase, drug & LoA

$14.95

+0.38 (+2.57%)

D 39Pipeline Score MedTech · Commercial
Market Cap
191.33 M
EPS
-0.79
P/E Ratio
-18.18 $
Value Trade
708.69 K
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    29.61 M

  • R&D Expenses

    6.71 M

  • Operating CF

    -4.85 M

  • Total Assets

    179.39 M

  • Total Liabilities

    179.39 M

  • Equity

    133.90 M

  • D/E Ratio

    12,345

-1.85 %
Week
-1.78 %
1 Month
39.46 %
3 Month
59.83 %
6 Month
-65.71 %
5 Year
325.14 %
All Time
Cash Data
Healthy

  • Cash Position

    66.79 M

  • Monthly Burn

    1.61 M

  • Runway

    40.1 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Apr 30, 2026
Overview
Volume
117.48 K
52 Week Range
7.87 - 16.24
% held by Insiders
5.44 %
% held by Institutions
93.85 %
Enterprise Value
176.05 M
Total Shares
14.42 M
Short %
4.44 %
Float Shares
12.68 M
Company Description
HQ: 32 WIGGINS AVENUE, BEDFORD, MA...
Founded:1992
Employees:235
https://www.anika.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D39
Pipeline Score
$269M
Pipeline Value
Valuation Signal
1
Drugs Scored
1.4x
rNPV / MCap
Top 52%
Micro Cap
(rank 435 of 905)
Percentile Rank
Anika Therapeutics Inc. faces pipeline headwinds (39/100), with $1.1B risk-adjusted pipeline value, led by Cingal in Osteoarthritis of the Knee (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Cingal
Small molecule		Knee OsteoarthritisPhase 3NCT0339003664% $1.1B COMPLETED 1,102 - -Jul 30, 2018 -May 31, 2023
Unlock Drug Pipeline Intelligence
ANIK Clinical Trial Results & History
Drug Name Indications Phase Date Trial Results Summary Title Source
Hyalofast
osteoarthritis,cartilage repair
Phase 3
2025-07-31
Hyalofast
osteoarthritis,cartilage repair
Phase 3
2025-07-31
Hyalofast
osteoarthritis,cartilage repair
Phase 3
2025-07-31
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ANIK
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Anika Therapeutics Inc. (ANIK) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ANIK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANIK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANIK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ANIK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ANIK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
ANIK Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Real-Time ANIK Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
ANIK Option Volume & Put-Call Ratio
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Anika Therapeutics Inc. (ANIK) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ANIK ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
All entries for ANIK are observational/device studies. Toggle "Show observational" to view them.